Introduction:
AC Immune and Takeda have signed an exclusive option license agreement for ACI-24.060, an active immunotherapy designed to delay or slow the progression of Alzheimer’s disease. ACI-24.060 is being investigated in a clinical trial to assess its safety and efficacy in patients with prodromal Alzheimer’s disease.
- Takeda has secured the exclusive global right to license ACI-24.060, a first-in-class active immunotherapy for the treatment of Alzheimer’s disease.
- ACI-24.060 is designed to induce a robust antibody response against toxic forms of Abeta, a protein associated with plaque formation in the brain.
- The ongoing clinical trial, ABATE, is assessing the safety, tolerability, and pharmacodynamic effects of ACI-24.060 in patients with prodromal Alzheimer’s disease.
- AC Immune will receive an upfront payment of $100 million, and potentially up to $2.1 billion in development and sales-based milestones, as well as tiered double-digit royalties on net sales.
- The read-outs from the ABATE trial are expected to be released in Q2/2024 and H2/2024, providing key data on the safety and efficacy of ACI-24.060.
Conclusion:
The exclusive agreement between AC Immune and Takeda for the development and commercialization of ACI-24.060 represents a significant milestone in the search for new treatments for Alzheimer’s disease. If successful, ACI-24.060 could potentially delay or slow the progression of the disease by targeting the toxic forms of Abeta that contribute to plaque formation in the brain. The ongoing ABATE trial will provide important data on the safety and efficacy of ACI-24.060, and the read-outs in 2024 will be eagerly anticipated by the scientific community.
